Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib

Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus

(2020) Keisuke Maeshima et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

(2020) Kristian Reich et al.   JAMA Dermatology

Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus

(2019) Marco Fornaro et al.   RHEUMATOLOGY

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

(2018) Daniel J Wallace et al.   LANCET

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

(2012) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus

(2011) Rachel Klein et al.   ARCHIVES OF DERMATOLOGY

Quality of life in cutaneous lupus erythematosus

(2011) Rachel Klein et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY